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Abstract
Purpose Recent studies suggest that African Americans
(AA) with chronic hepatitis C (CHC) differ from non-
Hispanic whites (NHW) with respect to the natural history
and mortality resulting from the complications of chronic
liver disease. The aim of this study was to examine the
demographics of a large cohort of CHC patients and
identify potential differences between AA and NHW.
Methods Thisisaretrospectiveanalysis,consistingof2,739
hepatitis C antibody-positive patients seen at Wayne State
University between 1995 and 2005. Patient demographics,
risk factors, comorbidities, alanine aminotransferase (ALT),
aspartate aminotransferase (AST), serum hepatitis C (HCV)
RNAlevels,genotype,andliverbiopsyresultswererecorded.
Results AA constituted 75.4%, NHW 22.5%, and Asians
or Hispanics 2.1% of the patients. Males predominated
(58%), and the mean age of AA and NHW was 50.0 and
45.3 years, respectively (P B 0.001). The most common
risk factor was injection drug use in 55.3% (AA 57.1% vs.
NHW 49.7%; P B 0.002). HCV RNA by PCR obtained in
2,407 patients was positive in 94.8%, with a high viral load
in 61%. Genotype 1 was signiﬁcantly more frequent in AA
(92.6%) than in NHW (70.6%, P B 0.001). AA had lower
median ALT levels (P B 0.001). In those patients who
were biopsied, there was no signiﬁcant difference in
ﬁbrosis between the two groups. Aspartate to platelet index
calculated in those patients who were not biopsied showed
signiﬁcantly lower ﬁbrosis scores in AA.
Conclusions In this large cohort of CHC patients from a
single institution, AA were older at presentation, had a
higher prevalence of genotype 1, but signiﬁcantly lower
ALT levels than NHW.
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Introduction
Hepatitis C virus (HCV) infection is the most common
chronic blood-borne infection in the United States, with an
estimated 3.9–5 million people having been infected [1, 2].
HCV infection can be a progressive disease, resulting in
cirrhosis that can lead to liver failure and/or hepatocellular
carcinoma (HCC). Decompensated cirrhosis associated
with HCV infection is the most frequent indication for liver
transplantation in the United States and Europe [3].
There is signiﬁcant racial disparity with respect to
chronic hepatitis C (CHC) in the United States, with the
highest prevalence of HCV infection in African Americans
(AA) (3.2%) and Hispanics (2.8%) than non-Hispanic
whites (NHW) (1.5%) [2]. AA, representing 12–13% of the
US population, account for 22% of the estimated 3.7 mil-
lion Americans who have CHC viremia [1, 2]. AA with
CHC are reported to have lower pretreatment alanine
aminotransferase (ALT) levels and less ﬁbrosis than NHW
[4]. Unfortunately, AA do not respond as well as NHW to
interferon (IFN)-based therapies [5–10]. The explanation
for this still remains unknown.
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have been reviewed in the general population [2], and
selected populations, such as veterans, prison inmates,
injection drug users [5, 11], and Hispanics [12, 13], there
are a few studies describing the demographics of AA
patients with CHC, and these have included only small
numbers of patients [14–19].
Our objectives were to study the demographics of a large
cohortofAApatientswithCHCfromasingleurbanmedical
center and to assess the clinical, biochemical, and histolog-
ical differences between AA and NHW patients with CHC.
Conﬁrmation and understanding of these differences could
provide insight into the differences in the natural history of
thediseaseand,perhaps,thedisparateresponsetoIFN-based
therapies between these 2 racial groups.
Materials and methods
Patients
The study population consisted of consecutive patients with
a positive HCV antibody seen in our outpatient practice
between January 1995 and July 2005. The majority of our
patients (78%) were referred by primary care physicians
from within the city of Detroit and by the General Internal
Medicine clinics from within our own institution. The
remaining patients were referred by primary care physicians
from other metropolitan Detroit communities. Referring
physicians had uniform criteria for patient referral. A posi-
tive test for HCV antibody was the most common reason for
referral. Data on all patients with CHC were entered into a
computer database using unique identiﬁer numbers for each
patient and medical record numbers, thereby preventing
duplicationofpatientdata.Informationonage,gender,race,
andriskfactorsforCHC,includinginjectiondruguse(IDU),
intranasal drugs, blood transfusions, tattoos, multiple sexual
partners, incarceration, hemodialysis, and other associated
medical conditions, was obtained by experienced clinicians
evaluating the patients. History of current and past alcohol
intakewasalsorecorded.Thesedatawererecordedonforms
speciﬁcally created for this purpose and then entered into a
computer database. Race was determined by self-reporting
as AA, Asian, Hispanic, or NHW. The computer database
was continually updated as data became available during
patients’ follow-up visits. The study was approved by the
institutional review board at Wayne State University School
of Medicine.
Methods
Anti-HCV serology was performed using the second gen-
eration ELISA for antibody (EIA II, Abbott Lab, Chicago,
IL). Testing for HCV RNA by reverse transcriptase-poly-
merase chain reaction (RT-PCR) was accomplished using
the superquant assay (PCR range: \200 to [2,000,000
copies/ml; National Genetics Institute, CA) or the Ampli-
cor HCV monitor test version 2.0 (PCR range: \2,500 to
[2,800,000 IU/ml; Roche Molecular, Pleasonton, CA)
performed in our laboratory. HCV genotype was tested
using the line probe Versant Inno-LiPa HCV-II genotype
assay (LiPA; Bayer Healthcare, Tarrytown, NY). Serum
samples were also tested for antibodies to hepatitis A virus
(anti-HAV), hepatitis B core antigen (anti-HBc), and hep-
atitis B surface antigen (HBsAg), alanine aminotransferase
(ALT), aspartate aminotransferase (AST), and albumin.
The Metavir score [20] for necroinﬂammation (grade
0 = no inﬂammation, grade 1 = mild inﬂammation, grade
2 = moderate inﬂammation, and grade 3 = severe
inﬂammation) and ﬁbrosis (stage 0 = no ﬁbrosis, stage
1 = portal ﬁbrosis, stage 2 = periportal ﬁbrosis, stage
3 = bridging ﬁbrosis, and stage 4 = established cirrhosis)
were recorded for all patients who underwent liver biopsy.
In order to assess the ﬁbrosis in the remaining patients, who
did not agree to liver biopsy, an AST to platelet index
(APRI) was calculated as follows: {(AST/ULN)/Plate-
lets(10
9/l)} 100.
Statistical analysis
For comparison of categorical data, Pearson’s chi-square or
Fisher’s exact tests were used. When AA and NHW
patients differed across a set of categories, follow-up
comparisons were made for each category separately. For
normally distributed continuous data, t tests were per-
formed. For continuous data that did not meet the
normality assumption, Mann–Whitney U tests were per-
formed. A P value of \0.05 was considered statistically
signiﬁcant.
Results
Age, gender, and race
A total of 2,739 anti-HCV-positive patients were included
in this analysis. As shown in Table 1, 2,035 patients were
AA and 616 NHW. The remaining 2.1% were Asians and
Hispanics. The selection criteria applied were identical in
all groups. A predominance of male gender was noted.
Nearly half of our patients were in their ﬁfth decade at
presentation, followed by those in their sixth decade. The
mean age of AA patients was higher than that of NHW
[49.98 and 45.34 years, respectively; P B 0.001]. The age
distribution by decade is shown in Table 1. Most patients
reported high-risk behavior in their 20s and taking into
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and 45.34 years, respectively), we estimated the duration
of disease to be approximately 20–25 years in most
patients, which was generally similar in both groups.
Risk factors
IDU was identiﬁed in most patients (two-thirds of whom
had multiple risk factors) and was the most common risk
factor observed, followed by blood transfusion prior to
1992 and intranasal drug use (Table 1). A signiﬁcantly
higher proportion of AA were injection drug users
(P B 0.002). Fourteen percent of the patients had no
identiﬁable risk factor. In the remaining patients, risk fac-
tors included employment in healthcare, hemodialysis,
tattoos, multiple sexual partners, and a spouse with history
of IDU. Alcohol consumption, both past and current, was
also noted to be similar in both groups (data not presented).
Laboratory data and liver histology
As shown in Table 2, HCV RNA determination by PCR
(qualitative or quantitative) was available for 2,407
patients, of whom 2,282 (95%) were positive. There was no
difference between AA and NHW in this regard. Quanti-
tative PCR for HCV RNA was available for 1,928 patients.
A high viral load was deﬁned as more than 2,000,000
copies/ml or 400,000 IU/ml. Sixty-one percent of the
patients had a high viral load. There was no signiﬁcant
difference in the viral load between AA and NHW.
Genotype was available for 1,683 patients and the vast
majority of AA were genotype 1 (P B 0.001). Genotypes
2, 3, and 4 were also identiﬁed but much less frequently in
AA than in NHW (Table 2).
The median ALT at presentation was signiﬁcantly lower
in AA (66 units/l, interquartile range = 44–96) than in
NHW (77, interquartile range = 50–121 P B 0.001).
Mean serum albumin was signiﬁcantly higher in NHW
(4.07 g/dl, SD = 0.36) than AA (3.90, SD = 0.7;
P B 0.001, data not shown). Although liver biopsy was
offered to all patients who were seen, only 1,414 (51.6%)
patients (AA = 49.6%, NHW = 57.8%) underwent
biopsy. Histological scoring showed lower grades of
inﬂammation in AA than in NHW (P = 0.047). NHW had
a higher median score for ﬁbrosis than AA, although this
did not achieve statistical signiﬁcance (P = 0.17). The
APRI evaluated in those patients who were not biopsied
showed a signiﬁcant difference (P B 0.04), with a greater
degree of ﬁbrosis in NHW than in AA (Table 2).
Serological markers for hepatitis A and B
Serological markers indicating previous exposure to hep-
atitis A and B viruses were available in 1,740 and 1,841
patients, respectively, and showed the prevalence of both
anti-HAV and anti-HBc antibodies to be signiﬁcantly
higher in AA than in NHW (Table 2). No difference in
HBsAg prevalence was observed between the 2 groups.
Discussion
The explanation for the differences in the natural history
and histological spectrum of CHC between AA and NHW
is still not well established. One might have anticipated, on
the basis of the decreased enzyme activity and less ﬁbrosis
that AA patients would have a more benign disease course.
However, for reasons that are unclear, the complications of
liver cirrhosis and the incidence of HCC are signiﬁcantly
Table 1 Characteristics of chronic hepatitis C patients seen at Wayne
State University, Detroit, MI, between 1995 and 2005
AA NHW P
n % n %
Total subjects 2,035 75.4 616 22.5 \0.001
a
Gender
Male 1,152 56.8 373 60.7 0.093
a
Female 875 43.2 242 39.3
Missing 8 1
Age (mean) 49.98 45.34 \0.001
b
14–29 23 1.1 28 4.6
30–39 117 5.8 104 17.1
40–49 851 42.2 303 49.8
50–59 816 40.4 139 22.8
60–69 164 8.1 24 3.9
70+ 47 2.3 11 1.8
Unknown 17 7
Risk factors \0.001
a
Injection drug use 1,070 57.1 279 49.7 \0.002
c
Blood transfusion 288 15.4 104 18.5 \0.074
c
Intranasal drugs 135 7.2 28 5.0 0.065
c
Multiple 38 2.0 9 1.6 0.522
c
Other
d 92 4.9 40 7.2
None 250 13.3 101 18.0 0.006
c
Missing data 162 55
a Chi-square test for overall difference in categories for AA and
whites
b t-Test for overall group in means for AA and NHW
c Chi-square test for differences in individual categories for AA and
NHW
d Other includes employment in healthcare, hemodialysis, tattoos,
multiple sexual partners, and a spouse with history of injection drug
use
Abbreviations: AA, African Americans; NHW, non-Hispanic whites
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123higher in AA than in NHW (6.1 vs. 2.8/100,000 persons,
respectively) [21–23]. AA men have a mortality rate from
HCC that is twice the rate observed among NHW men [23,
24]. Previous studies evaluating these issues have been
limited by the heterogeneity and small size of the popu-
lations studied [4, 14–17]. Our study of 2,739 patients with
CHC, of whom 2,035 were AA, constitutes the largest
demographic analysis emerging from any single institution.
The higher prevalence of HCC in AA has been attrib-
uted by many investigators to a higher prevalence of
coinfection with hepatitis B and hepatitis C because both
entities are considered predisposing factors for the devel-
opment of HCC. It is also conceivable that occult hepatitis
B infection, that is, presence of anti-HBc antibody alone,
could also contribute to the increased incidence of HCC in
AA. In fact, we did observe a signiﬁcantly higher
Table 2 Laboratory data and
liver histology of chronic
hepatitis C patients seen at
Wayne State University
Hospital, Detroit, MI, between
1995 and 2005
a Chi-square test for overall
difference in categories for AA
and NHW
b High:[2 million copies/ml or
[400,000 IU/ml
c Fisher’s exact test for overall
difference in categories for AA
and NHW
d Chi-square test for differences
in individual categories for AA
and NHW
e Fisher’s exact test for
differences in individual
categories for AA and NHW
f Mann–Whitney U test for
overall group in means for AA
and NHW
g Includes those with clinically
decompensated cirrhosis and
those with HCC
Abbreviations: AA, African
Americans; NHW, non-
Hispanic whites
AA NHW P
n % n %
Positive HCV RNA by PCR (Qual + Quant) 0.11
a
Positive 1,703 95.1 507 93.4
Negative 87 4.9 36 6.6
Viral load 0.25
a
Low 534 36 200 43
High
b 935 64 259 57
Genotype \0.001
c
Type 1 1,171 92.6 262 70.6 \0.001
d
Type 2 66 5.2 40 10.8 \0.001
d
Type 3 18 1.7 61 16.4 \0.001
d
Type 4 9 0.7 8 2.2 \0.03
e
Missing data
Anti-HAV IgG (total)
Positive 569 42.9 112 30.5 \0.001
a
Negative 756 57.1 255 69.5
Missing data 710 249
Anti-HBc IgG
Positive 826 58.8 161 41.7 \0.001
a
Negative 578 41.2 225 58.3
Missing data 631 230
HBsAg
Positive 57 3.6 21 4.9 0.24
c
Negative 1,510 96.4 410 95.1
Missing 468 185
Liver histology
Grade \0.04
f
0 (No inﬂammation) 77 8.4 23 7.3
1 454 49.2 138 44.1
2 312 33.8 117 37.4
3 79 8.6 31 9.9
4 0 0 4 1.3
Stage 0.16
f
0 (No ﬁbrosis) 179 17.7 65 18.3
1 (Portal) 274 27.2 83 23.3
2 (Periportal) 180 17.8 62 17.4
3 (Bridging ﬁbrosis) 158 15.7 47 13.2
4 (Cirrhosis)
g 218 21.6 99 27.8
APRI (mean) 0.65 0.78 0.04
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123prevalence in AA of serologic markers of previous expo-
sure to hepatitis B and hepatitis A than NHW. In addition,
lower socioeconomic status is correlated with both hepa-
titis A and B infections [25, 26]. Generally lower
socioeconomic status in AA patients could explain the
lower serum albumin levels observed, but we did not
speciﬁcally evaluate socioeconomic status in our patient
population.
Race and HCV genotype have important implications in
the treatment of CHC. Genotype 1 has consistently been
associated with a poorer response to IFN-based therapies,
especially in AA [7–10, 19, 27–29]. A signiﬁcantly higher
prevalence of genotype 1 in AA than in NHW was
observed in our cohort. Crosse et al. [15], Reddy et al. [18],
and Fleckenstein [19] have also made similar observations.
The question remains as to whether the increased preva-
lence of genotype 1 in AA patients reﬂects a host genetic
susceptibility or reﬂects a difference in mode of transmis-
sion. We also noted a higher prevalence of genotype 3 in
NHW (16.4%) than 1.4% in AA. The reasons for these
differences are unclear.
More recently Crosse et al. [15], in a cross-sectional
analysis of 87 AA and 136 NHW with CHC, showed lower
ﬁbrosis scores in AA. In a retrospective study of 355
patients (AA = 112), Wiley et al. [4] evaluated the pro-
gression of histological changes in the liver of CHC
patients over decades of exposure and noted that despite
the longer duration of infection in AA, ﬁbrosis scores were
signiﬁcantly lower than non-AA, especially in the third and
fourth decades. Modes of transmission, estimated duration
of infection, and alcohol abuse were similar in both groups.
McHutchinson et al. [27] noted that AA were older at
presentation, but these investigators did not observe a
lower rate of cirrhosis. However, the number of AA in this
large multicenter study was small, accounting for only 3%
of the total patients enrolled. In contrast, Sterling et al. [16]
in a study of 302 patients from a correctional facility
(AA = 49%) found the overall spectrum of HCV-related
liver disease to be similar in AA and NHW, without sig-
niﬁcant differences in the total histological activity index
(HAI) scores for ﬁbrosis and inﬂammation. Although the
utility of the APRI has been controversial [30], recent
studies by Snyder et al. [31] and Shaheen and Myers [32]
have described the APRI to be a good estimator of hepatic
ﬁbrosis and an important tool in excluding signiﬁcant
HCV-related ﬁbrosis. Hence, in order to obtain an indirect
measure of the liver ﬁbrosis in those patients who were not
biopsied, we utilized the APRI and noted signiﬁcantly
lower ﬁbrosis scores in AA.
This is a retrospective study with inherent limitations.
Although complete information was available regarding
the race, gender, age, and risk factors, information about
the viral load, genotype, and liver biopsy was not available
for all patients. In addition, many patients seen between
1995 and 2000 did not have HCV RNA quantitation
because access to this assay was not universally available.
Even fewer patients had genotyping done. We believe the
sampling obtained for each of these parameters was rep-
resentative for both the NHW and the AA cohorts.
The importance of steatosis and insulin resistance on
treatment response has gained emphasis more recently. Our
data collection started in 1995 when these factors were not
being evaluated, and hence this information was not
recorded. Liver biopsy was recommended for all patients;
however, those patients who did not wish to be treated
often refused liver biopsy. Patient refusal of treatment and
lack of adherence with follow-up visits were the 2 most
common reasons for our inability to complete all compo-
nents of the initial assessments.
In summary, the results derived from this large study of
2,739 patients with CHC conﬁrm that AA when compared
with NHW are older at presentation, are more likely to be
injection drug users, infected with genotype 1, have lower
ALT and albumin, and less hepatic ﬁbrosis. AA also have a
higher prevalence of previous exposure to hepatitis A and
B. Although these ﬁndings have been observed by other
investigators in much smaller groups of AA, this report
conﬁrms these observations in a much larger group of AA
seen in a single institution.
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